Saturday 17 October 2026
Export PAHC’s income statement to Excel — free account
Phibro Animal Health Corporation
PAHC Healthcare Drug Manufacturers Specialty & Generic
Phibro Animal Health Corporation’s revenue for fiscal 2026 (year ended June 2026) was $1.5 billion, up 17.1% from fiscal 2025. In the quarter to June 2026, revenue grew 4.77%, EPS grew 28.6%, free cash flow fell 35.7% and total debt rose 1.96%, each against the same quarter a year earlier. Dividend growth for ten consecutive years, revenue growth for five; insiders bought in the last twelve months.
38.82
0.84
+2.21%
Follow PAHC
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
12.76 | 23.64 | 16.46 | 24.23 |
+8 more quarters Free account |
P/S ratio |
0.84 | 1.50 | 1.03 | 1.17 | |
P/FCF ratio |
129.04 | 175.62 | 32.02 | 47.83 | |
P/Operating CF |
52.84 | 138.40 | 78.25 | 176.31 | |
P/B ratio |
3.30 | 6.20 | 4.56 | 5.26 | |
Price to Tangible BV |
4.31 | 8.30 | 6.32 | 7.56 | |
EV/Sales |
1.27 | 1.93 | 1.48 | 1.64 | |
EV/EBITDA |
7.75 | 12.46 | 9.79 | 11.74 | |
EV/Operating CF |
27.90 | 43.87 | 23.32 | 29.92 | |
EV/FCF |
195.01 | 227.15 | 45.91 | 67.01 | |
Quick Ratio |
1.01 | 1.06 | 1.03 | 1.12 | |
Current Ratio |
2.96 | 3.17 | 3.05 | 3.09 | |
Net Debt/EBITDA |
10.48 | 11.41 | 10.30 | 10.17 | |
Debt/Assets |
48.81% | 50.90% | 52.03% | 53.62% | |
Debt/Equity |
1.90 | 2.03 | 2.20 | 2.38 | |
Asset Turnover |
1.06 | 1.09 | 1.09 | 1.19 | |
Operating CF/Net income |
1.11 | 0.67 | 0.70 | 0.35 | |
Capex/Depreciation |
(1.35) | (1.18) | (0.82) | (1.03) | |
Interest Coverage |
4.73 | 4.28 | 4.28 | 4.25 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
21.74% | 21.12% | 22.02% | 18.83% | |
Intangible Assets out of Total Assets |
0.06 | 0.06 | 0.07 | 0.07 | |
Share Based Compensation of Revenue |
0.10% | 0.11% | 0.12% | 0.09% | |
Graham Net Nets |
(0.14) | (0.08) | (0.14) | (0.15) | |
Graham Number |
22.94 | 21.67 | 20.46 | 17.00 | |
Earnings Yield |
7.83% | 4.23% | 6.08% | 4.13% | |
Free Cash Flow Yield |
0.77% | 0.57% | 3.12% | 2.09% | |
Revenue per Share |
9.79 | 9.46 | 9.22 | 8.98 | |
Operating CF per Share |
0.59 | 0.40 | 0.48 | 0.23 | |
Capex per Share |
(0.47) | (0.38) | (0.27) | (0.34) | |
Free Cash Flow per Share |
0.13 | 0.02 | 0.20 | (0.11) | |
Cash per Share |
2.02 | 1.91 | 1.84 | 2.10 | |
Shareholders Equity per Share |
9.51 | 8.92 | 8.20 | 7.69 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
9.51 | 8.92 | 8.20 | 7.69 | |
Free Cash Flow |
5.23 | 0.89 | 8.26 | (4.50) | |
Working Capital |
619.04 | 612.20 | 579.82 | 565.66 | |
Capital Expenditures |
(18.87) | (15.32) | (11.10) | (13.81) | |
Net Current Asset Value |
(180.26) | (189.22) | (211.01) | (238.04) | |
EV/EBIT |
9.90 | 16.12 | 12.86 | 15.95 | |
Capex to Sales |
0.05 | 0.04 | 0.03 | 0.04 | |
Price to Operating Income |
6.55 | 12.46 | 8.97 | 11.39 | |
| Other line items | |||||
Average Receivables |
233.39 | 209.53 | 203.83 | 189.34 | |
Average Payables |
132.76 | 130.63 | 116.37 | 108.56 | |
Average Inventory |
489.65 | 494.04 | 472.29 | 372.17 | |
Average Assets |
1,431.07 | 1,381.19 | 1,345.53 | 1,175.91 | |
Average Common Equity |
335.58 | 313.91 | 289.58 | 285.10 |
Columns are period end dates